ASSOCIATION OF NON-SECRETORY MULTIPLE MYELOMA AND HYPOTHYROIDISM: A RARE CASE REPORT

Authors

  • F SHAHZAD Saidu Group of Teaching Hospitals, Swat, Pakistan
  • N ULLAH Khyber Teaching Hospital (MTI), Peshawar, Pakistan
  • M YOUSAF Peshawar Institute of Cardiology, Peshawar, Pakistan
  • M AITIZAZ Khyber Teaching Hospital (MTI), Peshawar, Pakistan
  • MZ KHAN Saidu Medical College, Swat, Pakistan
  • F ULLAH Khyber Teaching Hospital (MTI), Peshawar, Pakistan

DOI:

https://doi.org/10.54112/pjicm.v5i01.74

Keywords:

Hypothyroidism, atypical symptoms, bone marrow biopsy, non-secretory multiple myeloma (NSMM)

Abstract

One uncommon subtype of MM is non-secretory multiple myeloma (NSMM), and its main characteristic is the lack of observable monoclonal proteins. The coexistence of hypothyroidism and MM is very rare, and little is known about their interaction. Presentation of the case: A known case of hypothyroidism, presented with fever, shortness of breath, and fatigue. Lytic lesions on skull X-ray, lack of proteins on protein electrophoresis, and bone marrow biopsy confirmed the diagnosis. The patient was treated with cyclophosphamide and dexamethasone. Discussion: This case demonstrates how challenging it can be to identify NSMM, especially when typical MM symptoms are absent. Since the concurrence of MM and hypothyroidism is very uncommon, more research is required. Conclusion: This study highlights the need for a multidisciplinary approach for the diagnosis and treatment of rare MM variants due to their atypical presentations. Further study is required to elucidate the underlying mechanisms and therapeutic implications of this association.

References

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA: a cancer journal for clinicians. 2018;68(1):7-30.

Ludwig H, Novis Durie S, Meckl A, Hinke A, Durie B. Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment. The oncologist. 2020;25(9):e1406-e1413.

Charliński G, Jurczyszyn A. Non-secretory multiple myeloma: Diagnosis and management. Advances in Clinical and Experimental Medicine. 2022;31(1):95-100.

Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The lancet oncology. 2014;15(12):e538-e548.

Cavo M, Galieni P, Gobbi M, et al. Nonsecretory multiple myeloma: presenting findings, clinical course and prognosis. Acta haematologica. 1985;74(1):27-30.

Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood, The Journal of the American Society of Hematology. 2001;97(9):2900-2902.

Corso A, Mangiacavalli S. Non-secretory myeloma: ready for a new definition? Mediterranean journal of hematology and infectious diseases. 2017;9(1)

Al-Azem H, Khan AA. Hypoparathyroidism. Best practice & research Clinical endocrinology & metabolism. 2012;26(4):517-522.

Ueki K, Tsuchida A, Murakami H, et al. Hypoparathyroidism during alpha-INF therapy in a patient with multiple myeloma. Journal of medicine. 1989;20(5-6):391-397.

Dispenzieri A. POEMS syndrome: 2019 update on diagnosis, risk‐stratification, and management. American journal of hematology. 2019;94(7):812-827.

Ashur-Fabian O, Cohen K, Hercbergs A, Ellis M. Novel Association Between Thyroid Hormones and Multiple Myeloma Cell Proliferation: a MAPK Dependent Activity. Blood. 2009;114(22):2836.

Albagoush S, Shumway C, Azevedo A. Multiple Myeloma. 2023 Jan 30. StatPearls [Internet] Treasure Island (FL): StatPearls Publishing. 2024;

Cohen K, Ellis M, Khoury S, Davis PJ, Hercbergs A, Ashur-Fabian O. Thyroid hormone is a MAPK-dependent growth factor for human myeloma cells acting via αvβ3 integrin. Molecular Cancer Research. 2011;9(10):1385-1394.

Cohen K, Ellis M, Shinderman E, et al. Relevance of the thyroid hormones–αvβ3 pathway in primary myeloma bone marrow cells and to bortezomib action. Leukemia & lymphoma. 2015;56(4):1107-1114.

Cohen K, Flint N, Shalev S, et al. Thyroid hormone regulates adhesion, migration and matrix metalloproteinase 9 activity via αvβ3 integrin in myeloma cells. Oncotarget. 2014;5(15):6312.

Jordan K, Proskorovsky I, Lewis P, et al. Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study. Supportive Care in Cancer. 2014;22:417-426.

DE SANCTIS V. Pain in blood cancers. INDIAN JOURNAL OF PALLIATIVE CARE. 2011;17:175-183.

Johnsen AT, Tholstrup D, Petersen MA, Pedersen L, Groenvold M. Health related quality of life in a nationally representative sample of haematological patients. European journal of haematology. 2009;83(2):139-148.

Kyle RA, BUADI FI, RAJKUMAR SVE. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). Oncology (Williston Park, NY). 2011;25(7):578.

Downloads

Published

2025-06-20

How to Cite

SHAHZAD, . F., ULLAH, . N., YOUSAF, . M., AITIZAZ, M., KHAN, M., & ULLAH , F. (2025). ASSOCIATION OF NON-SECRETORY MULTIPLE MYELOMA AND HYPOTHYROIDISM: A RARE CASE REPORT. Pakistan Journal of Intensive Care Medicine, 5(01), 74. https://doi.org/10.54112/pjicm.v5i01.74

Issue

Section

Case Report